免疫实践咨询委员会关于带状疱疹疫苗使用的建议。
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.
作者信息
Dooling Kathleen L, Guo Angela, Patel Manisha, Lee Grace M, Moore Kelly, Belongia Edward A, Harpaz Rafael
出版信息
MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):103-108. doi: 10.15585/mmwr.mm6703a5.
Abstract
On October 20, 2017, Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline, [GSK] Research Triangle Park, North Carolina), a 2-dose, subunit vaccine containing recombinant glycoprotein E in combination with a novel adjuvant (AS01), was approved by the Food and Drug Administration for the prevention of herpes zoster in adults aged ≥50 years. The vaccine consists of 2 doses (0.5 mL each), administered intramuscularly, 2-6 months apart (1). On October 25, 2017, the Advisory Committee on Immunization Practices (ACIP) recommended the recombinant zoster vaccine (RZV) for use in immunocompetent adults aged ≥50 years.
摘要
2017年10月20日，重组带状疱疹疫苗（佐剂）（欣安立适，葛兰素史克公司，北卡罗来纳州三角研究园），一种两剂次的亚单位疫苗，含重组糖蛋白E并与新型佐剂（AS01）联合，获美国食品药品监督管理局批准用于预防50岁及以上成人的带状疱疹。该疫苗由两剂次（各0.5毫升）组成，通过肌肉注射给药，间隔2至6个月（1）。2017年10月25日，免疫实践咨询委员会（ACIP）建议在免疫功能正常的50岁及以上成人中使用重组带状疱疹疫苗（RZV）。
相似文献
1
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.
MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):103-108. doi: 10.15585/mmwr.mm6703a5.
2
Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(3):80-84. doi: 10.15585/mmwr.mm7103a2.
3
Update on recommendations for use of herpes zoster vaccine.
MMWR Morb Mortal Wkly Rep. 2014 Aug 22;63(33):729-31.
4
Update on the advisory committee on immunization practices' recommendations for use of herpes zoster vaccine.
J Am Osteopath Assoc. 2011 Oct;111(10 Suppl 6):S31-3.
5
Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
J Manag Care Spec Pharm. 2020 Dec;26(12):1567-1575. doi: 10.18553/jmcp.2020.20251. Epub 2020 Oct 12.
6
Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV).
Vaccine. 2018 Nov 19;36(48):7408-7414. doi: 10.1016/j.vaccine.2018.09.018. Epub 2018 Oct 26.
7
Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines.
J Virol. 2021 May 24;95(12). doi: 10.1128/JVI.00240-21.
8
Which patients should receive the herpes zoster vaccine?
JAAPA. 2019 Sep;32(9):18-20. doi: 10.1097/01.JAA.0000578788.69674.2b.
9
Cost-effectiveness of the Recommendations of the Advisory Committee on Immunization Practices for the Recombinant Adjuvanted Zoster Subunit Vaccine.
JAMA Intern Med. 2018 Sep 1;178(9):1277-1278. doi: 10.1001/jamainternmed.2018.3200.
10
Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2351584. doi: 10.1080/21645515.2024.2351584. Epub 2024 Jun 5.
引用本文的文献
1
Molecular ingredients of an immunogen for long-lasting IgG.
Front Immunol. 2025 Aug 19;16:1639371. doi: 10.3389/fimmu.2025.1639371. eCollection 2025.
2
Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudy.
RMD Open. 2025 Aug 12;11(3):e005521. doi: 10.1136/rmdopen-2025-005521.
3
Effectiveness and safety of the recombinant zoster vaccine in adult patients with systemic lupus erythematosus: a claims-based retrospective cohort study in the USA.
RMD Open. 2025 Aug 7;11(3):e005839. doi: 10.1136/rmdopen-2025-005839.
4
Prolonged Neurological and Musculoskeletal Symptoms Following Shingrix Vaccination.
Reports (MDPI). 2024 Oct 9;7(4):83. doi: 10.3390/reports7040083.
5
Research Progress on Varicella-Zoster Virus Vaccines.
Vaccines (Basel). 2025 Jul 4;13(7):730. doi: 10.3390/vaccines13070730.
6
The safety of co-administration of recombinant zoster vaccine (Shingrix) and influenza vaccines in the elderly in VAERS during 2018-2024.
Hum Vaccin Immunother. 2025 Dec;21(1):2525603. doi: 10.1080/21645515.2025.2525603. Epub 2025 Jul 11.
7
2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association.
Diabetes Metab J. 2025 Jul;49(4):582-783. doi: 10.4093/dmj.2025.0469. Epub 2025 Jul 1.
8
Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications.
EClinicalMedicine. 2025 May 9;83:103241. doi: 10.1016/j.eclinm.2025.103241. eCollection 2025 May.
9
Vaccination coverage, willingness and determinants of herpes zoster vaccine among individuals aged 50 and above in Ningbo, China: A population-based cross-sectional study.
Hum Vaccin Immunother. 2025 Dec;21(1):2524247. doi: 10.1080/21645515.2025.2524247. Epub 2025 Jul 2.
10
Human Alpha Herpesviruses Infections (HSV1, HSV2, and VZV), Alzheimer's Disease, and the Potential Benefits of Targeted Treatment or Vaccination-A Virological Perspective.
Vaccines (Basel). 2025 May 27;13(6):572. doi: 10.3390/vaccines13060572.
本文引用的文献
1
Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults.
Hum Vaccin Immunother. 2018 Jun 3;14(6):1370-1377. doi: 10.1080/21645515.2018.1442162. Epub 2018 Mar 21.
2
Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study.
Am J Epidemiol. 2018 Jan 1;187(1):161-169. doi: 10.1093/aje/kwx245.
3
Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.
JAMA Intern Med. 2018 Feb 1;178(2):248-258. doi: 10.1001/jamainternmed.2017.7431.
4
Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
Vaccine. 2018 Jan 2;36(1):148-154. doi: 10.1016/j.vaccine.2017.11.019. Epub 2017 Nov 22.
5
Herpes zoster vaccine live: A 10 year review of post-marketing safety experience.
Vaccine. 2017 Dec 19;35(52):7231-7239. doi: 10.1016/j.vaccine.2017.11.013. Epub 2017 Nov 22.
6
Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older.
J Infect Dis. 2017 Dec 12;216(11):1352-1361. doi: 10.1093/infdis/jix481.
7
Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
J Infect Dis. 2017 Dec 12;216(11):1343-1351. doi: 10.1093/infdis/jix482.
8
Effectiveness and Duration of Protection Provided by the Live-attenuated Herpes Zoster Vaccine in the Medicare Population Ages 65 Years and Older.
Clin Infect Dis. 2017 Mar 15;64(6):785-793. doi: 10.1093/cid/ciw854.
9
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
N Engl J Med. 2016 Sep 15;375(11):1019-32. doi: 10.1056/NEJMoa1603800.
10
Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient.
BMJ Case Rep. 2016 May 4;2016:bcr2015212688. doi: 10.1136/bcr-2015-212688.
Zotero 插件